[(3aR,4S,5R,6S,7aS)-2-(dimethylamino)-5-methyl-4-phenylmethoxy-3a,4,5,6,7,7a-hexahydro-1,3-benzothiazol-6-yl]methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [(3aR,4S,5R,6S,7aS)-2-(dimethylamino)-5-methyl-4-phenylmethoxy-3a,4,5,6,7,7a-hexahydro-1,3-benzothiazol-6-yl]methanol
• 化学式: C₁₈H₂₆N₂O₂S
• 分子量: 334.5
• InChiKey: JSMASCUOKJPYCR-ZUOZUFPHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
  申请人：Selnick Harold G.

  公开号：US20140206665A1

  公开（公告）日：2014-07-24

  The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.

  本发明涉及用于选择性抑制糖苷酶的化合物，以及包括该化合物的药物组合物和治疗与O-GlcNAcase缺乏或过度表达以及O-GlcNAc的积累或缺乏相关的疾病和障碍的方法。
• PERMEABLE GLYCOSIDASE INHIBITORS AND USES THEREOF
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150152127A1

  公开（公告）日：2015-06-04

  The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.

  本发明涉及化合物和制药配方，其中包括这些化合物，这些化合物可用作O-链接N-乙酰葡萄糖胺酶（O-GlcNAcase）抑制剂，因此可能有助于治疗某些疾病，例如阿尔茨海默病，包括减少NFTs和/或过度磷酸化的tau。本发明还涉及将这些化合物用作O-GlcNAcase成像剂。
• US9126957B2
  申请人：——

  公开号：US9126957B2

  公开（公告）日：2015-09-08